In vitro toxicity of ET-743 and aplidine, two marine-derived antineoplastics, on human bone marrow haematopoietic progenitors: Comparison with the clinical results

European Journal of Cancer

Volumn 38, Issue 10, 2002, Pages 1395-1404

  Albella, B ^a   Faircloth, G ^b   Lopez Lazaro L ^c   Guzman C ^c   Jimeno, J ^c   Bueren, J A ^a  

^a CIEMAT   (Spain)

^b PharmaMar USA Inc   (United States)

^c PHARMAMAR S A   (Spain)

Author keywords

Aplidine; ET 743; Toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; DEHYDRODIDEMNIN B; DOXORUBICIN; TRABECTEDIN;

ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; BONE MARROW CELL; CANCER; CANCER CELL CULTURE; CELL TYPE; CELL VIABILITY; CLINICAL TRIAL; COLONY FORMING UNIT GM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG HALF LIFE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; INCUBATION TIME; MAXIMUM TOLERATED DOSE; MEGAKARYOCYTE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; BONE MARROW DISEASES; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; DEPSIPEPTIDES; DIOXOLES; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; HEMATOPOIETIC STEM CELLS; HUMANS; INHIBITORY CONCENTRATION 50; ISOQUINOLINES; NEOPLASMS; PEPTIDES, CYCLIC; TETRAHYDROISOQUINOLINES; TUMOR CELLS, CULTURED;

EID: 0036288919     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(01)00245-3     Document Type: Article

References (40)

1. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by Ecteinascidin 743, a potent antitumor compound from the caribbean tunicate Ecteinascidin turbinata
2. NMR based model of an Ecteinascidin 743-DNA adduct
3. Ecteinascidin-743 (ET-743), a natural marine compound with a unique mechanism of action
4. Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743
5. Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation
6. Novel antiviral and cytotoxic agent
7. Is Aplidine acting as an Ornithine Decarboxylase (ODC) inhibitor?
8. Changes in gene expression in tumor cells exposed to the two marine compounds, ET-743 and Aplidine, by using cDNA microarrays
9. High antitumour activity of ET-743 against human tumor xenografts from melanoma, non small cell lung and ovarian cancers
10. Progress in the acquisition of new marine-derived anticancer Compounds: Development of Ecteinascidin-743 (ET-743)
11. A phase I and pharmacokinetic (PK) study of ET-743 evaluating a 3 hours (h) intravenous (iv) infusion (I) in patients (pts) with solid tumors
12. A phase I study of Ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors
13. Final results of a phase I and pharmacokinetic (PK) study of the marine minor groove binder ET-743 on a daily×5 schedule
14. Phase I and pharmacokinetic study of Ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies
15. Ecteinascidin-743 (Et-743) in taxane (T)/anthracycline (A) pretreated advanced/metastatic breast cancer (A/Mbc) patients (pts): Preliminary results with the 24 hour (H) continuous infusion (Ci) q3week schedule
16. Ecteinascidin (Et-743) shows promising activity in distinct populations of sarcoma patients: Summary of 3 U.S.-based phase II trials
17. Phase II study of ET-743 in advanced soft tissue sarcoma (Asts) in adults: A STBSG-EORTC trial
18. Phase I and pharmacokinetic (Pk) study of Aplidine (Apl) using a q 24-hour, weekly schedule
19. Phase I and pharmacokinetic study of aplidine, a marine compound, given as a 24 h infusion every 2 weeks in patients (pts) with advanced non-Hodgkin lymphoma (NHL)
20. Phase I study of aplidine (APL) in a 1 hour daily infusion×5 q 3 weeks in patients (pts) with solid tumors and intermediate grade non Hodgkin lymphomas: A National Cancer Institute of Canada-Clinical Trials Group (NCIC-CTG) study
21. A phase I study of aplidine (APL) a marine derived compound, given as a 1 h infusion weekly×3 in advanced solid tumors and non-Hodgkin lymphoma patients (pts.)
22. Preclinical characterization of Aplidine, a new marine anticancer depsipeptide
23. In vitro activity of aplidine, a new marine-derived anti-cancer compound, on freshly explanted clonogenic human tumor cells and haematopoietic precursor cells
24. In vitro schedule-dependency of myelotoxicity and cytotoxicity of Ecteinascidin 743 (ET-743)
25. Quantitative determination of Ecteinascidin 743 in human plasma by miniaturized high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry
26. Analysis of aplidine (dehydrodidemnin B), a new marine-derived depsipeptide, in rat biological fluids by liquid chromatography-tandem mass spectrometry
27. Compartmental and non-compartmental pharmacokinetics
28. In vivo-in vitro correlation of myelotoxicity of 9-methoxypyrazoloacridine (NSC-366140, PD115934) to myeloid and erythroid hematopoietic progenitors from human, murine, and canine marrow
29. Differential toxicity of camptothecin, topotecan and 9-aminocamptothecin to human, canine, and murine myeloid progenitors (CFU-GM) in vitro
30. Estimation of the haematological toxicity of minor groove alkylators using tests on human cord blood cells
31. Haematotoxicity of mycotoxins
32. Activity of Ecteinascidin, a novel marine compound against human tumor colony forming units
33. Phthalascidin, a synthetic antitumor agent with potency and mode of action comparable to ecteinascidin 743
34. Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumor cells is maintained
35. Effects of L-phenylalanine mustard and L-buthionine sulfoximine on murine and human hematopoietic progenitor cells in vitro
36. Incomplete cross-resistance between ET-743 and standard chemotherapeutic agents against primary tumours in human tumor cloning assay
37. Doxorubicin
38. Indirect-response model for the time course of leukopenia with anticancer drugs
39. Evaluation of platelet kinetics following porcine and mechanical valve replacement
40. Method development for a prevalidation study of the in vitro GM-CFU assay for predicting myelotoxicity